tenoxicam Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tenoxicam, sold under the brand name Mobiflex among others, is a nonsteroidal anti-inflammatory drug (NSAID). It is used to relieve inflammation, swelling, stiffness, and pain associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, and periarthritis of the shoulders or hips.   Wikipedia

Chemistry

  • SMILES: CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O
  • InChIKey: LZNWYQJJBLGYLT-UHFFFAOYSA-N
  • Mol. Mass: 337.38
  • ALogP: 1.64
  • ChEMBL Molecule:
    tenoxicam  
More Chemistry

Pharmacology

Alternative names

4-hydroxy-2-methyl-n-2-pyridyl-2h-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide | apo-tenoxicam | artriunic | mobiflex | novo-tenoxicam | reutenox | ro 12-0068 | ro-12-0068 | ro-120068000 | tenoxicam | ténoxicam | tenoxicamum | tilcotil

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (1)


 

Arthritis, Rheumatoid

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Analgesia (Phase 2)

Arthritis ()

Arthrocentesis (Phase 1)

Molar, Third (Phase 4)

Obstetrics (Phase 2)

Pain (Phase 4)

Pain, Postoperative (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue